ABCAM Plc Total Voting Rights (7603V)
February 01 2017 - 7:09AM
UK Regulatory
TIDMABC
RNS Number : 7603V
ABCAM Plc
01 February 2017
For immediate release 01 February 2017
ABCAM PLC
("Abcam" or "Company")
Total Voting Rights - Voting Rights and Capital
In conformity with the Disclosure Rules and Transparency Rules,
provision 5.6.1, the Company notifies the market of the
following:
The Company's issued share capital consists of 203,601,806
Ordinary Shares of 0.2p each with voting rights. The Company does
not hold any shares in Treasury.
The above figure of 203,601,806 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in the Company under the FCA's Disclosure and
Transparency Rules.
Date of Notification: 01 February 2017
For further information please contact:
+ 44 (0) 1223
Abcam 696 000
Suzanne Smith, Company Secretary
J.P.Morgan Cazenove - Nominated Adviser + 44 (0) 20
& Corporate Broker 7742 4000
James Mitford / Chris Cargill
FTI Consulting
Ben Atwell / Brett Pollard / Natalie +44 (0) 20
Garland-Collins 3727 1000
Notes to Editors
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's twelve locations are in the world's leading life science
research hubs, enabling local services and multi-language support.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 100 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRUGURUPUPMGPG
(END) Dow Jones Newswires
February 01, 2017 07:09 ET (12:09 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Sep 2023 to Sep 2024